---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-031103"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2026-06-29T20:51:57+00:00"
generated_at: "2026-06-29T20:53:21.081277+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elite Pharma reports FY2026 revenue of $148.9M (+77% YoY), operating income $49.1M (+151%)

## Summary
- Consolidated revenue $148.9M, up $64.8M (77%) vs prior year; operating profit $49.1M, up $29.5M (151%).
- Growth driven by full-year contribution of Lisdexamfetamine, plus launches of Oxycodone Acetaminophen, Naltrexone, and Phentermine tablets.
- Conference call on June 30, 2026 at 11:30 AM EDT; dial-in 1-800-346-7359 (domestic), conference number 98840.
- Stockholders may submit financial questions by 7:00 PM EDT on June 29, 2026 via dianne@elitepharma.com.

## SEC filing metadata
- accession: 0001493152-26-031103
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2026-06-29T20:51:57+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315226031103/0001493152-26-031103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315226031103/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-031103
- JSON: https://secwatch.observer/filing/0001493152-26-031103.json
- Plain text: https://secwatch.observer/filing/0001493152-26-031103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.